Currently, doctors treating patients with breast cancer make treatment decisions and predictions based largely on the location and size of the tumor and if the cancer has spread, or metastasized, to lymph nodes and distant sites of the body.
But not all patients who are similar in terms of these clinical indicators get the same benefits from treatment.
These new findings could remedy that situation. Such differences in gene activity may be used as biomarkers to identify which treatments can be individually matched.
Over the past five years, gene expression profiles have been identified that appear to be predictive for cancer patients, especially for breast cancer patients. But these tests show very little overlap in their gene lists, and thus it is not known just how distinct these different assays might be.
According to Dr. Charles M. Perou, assistant professor of genetics and pathology at the UNC School of Medicine and a member of the UNC Lineberger Comprehensive Cancer Center, some of the predictive assays are available commercially and others are under study in clinical trials in which treatment decisions, including whether or not to use chemotherapy, are being made based on them.
"An important and unanswered question, however, is whether these assays actually disagree or agree concerning outcome predictions for the individual patient," Perou said. "I think this is a very important point because if they disagree then it becomes difficult to determine which to use and when, and which are more robust and helpful."
To compare the individual predictions made by these different genomic tests, Perou and his colleagues at UNC and at The Netherlands Cancer Institute in Amsterdam, The Netherlands, studied the concordance of five different predictors that were all applied to a single data set of 295 tumor samples for which patient survival data was available – relapse-free survival and overall survival.
Writing in the Aug. 10 issue of the New England Journal of Medicine, the researchers note that four predictors showed "significant agreement" in their outcome predictions on individual breast cancer patients, despite having little gene overlap. Of the three predictors showing the greatest concordance, two were the main assays that are commercially available and being used to guide clinical trials.
"If one assay said this patient was going to do poorly, then so did the other two," Perou said, noting that although the two commercial assays overlapped each other only by one gene, they were in 80 percent agreement with each other.
"This is good news for breast cancer patients. It means that different groups have independently arrived at tests which agree with each other and that they all do add information not provided by existing clinical tests," Perou said.
For example, several of the predictors in this study appear to predict the likelihood of breast cancer recurrence in various populations of women with node-negative disease.
Such information would be useful for identifying women who are unlikely to experience recurrence and, thus, potentially unlikely to benefit from chemotherapy.
"We find our results encouraging and interpret them to mean that although different gene sets are being used, they are each tracking a common set of biological characteristics that are present across different breast cancers and are making similar outcome predictions," Perou said.
L. H. Lang | EurekAlert!
Researchers simplify tiny structures' construction drip by drip
12.11.2018 | Princeton University, Engineering School
Mandibular movement monitoring may help improve oral sleep apnea devices
06.11.2018 | Elsevier
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly
The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...
Scientists developed specially coated nanometer-sized vehicles that can be actively moved through dense tissue like the vitreous of the eye. So far, the transport of nano-vehicles has only been demonstrated in model systems or biological fluids, but not in real tissue. The work was published in the journal Science Advances and constitutes one step further towards nanorobots becoming minimally-invasive tools for precisely delivering medicine to where it is needed.
Researchers of the “Micro, Nano and Molecular Systems” Lab at the Max Planck Institute for Intelligent Systems in Stuttgart, together with an international...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
12.11.2018 | Life Sciences
12.11.2018 | Materials Sciences
12.11.2018 | Physics and Astronomy